mdi Consultants, IncWhy Medical Device Startups Struggle With FDA Regulatory Approval: 10 Common Mistakes
Quick Answer
- Medical device startups most often fail to reach market on time because they treat FDA regulatory compliance as a final step rather than building it into product design from the concept stage.
- The 10 most common causes of medical device startup regulatory struggles are: incorrect device classification, missing design controls, incomplete technical documentation, inadequate ISO 14971 risk management, insufficient verification and validation testing, missing human factors studies, poor supplier qualification, delayed ISO 13485/QMSR implementation, no clear FDA/EU MDR/UKCA strategy, and underestimating the time and cost of approval.
- mdi Consultants has provided FDA regulatory consulting to the medical device industry for over 48 years and has observed these same 10 failure points recur across startups of every size.
Understanding what a company should do to bring a new device design to market is very important to assure a successful launch.
The most successful medical device companies do not treat regulatory compliance as the final step. They build compliance into the product from the concept stage itself.
Why a Strong Regulatory Strategy Matters
A well-built regulatory strategy delivers measurable business benefits, not just compliance checkboxes. A strong regulatory strategy can:
- Reduce time to market
- Avoid costly redesign
- Improve investor confidence
- Accelerate global market access
- Increase the probability of successful approval
The 10 Most Common Reasons Medical Device Startups Struggle
Each of these issues is a recurring, documented cause of delayed or rejected medical device submissions
1. Incorrect Device Classification
A device’s classification — Class I, II, or III in the U.S., or Class A, B, C, or D under EU MDR — determines which regulatory pathway, documentation, and review timeline apply. Classification also depends on the device’s label claims and Indications for Use (IFU), since how a company markets a device can change its classification.
Key takeaway: Not knowing where a device falls results in missing documentation and an inaccurate understanding of the FDA or notified-body review timeline.
2. Design Controls Not Incorporated During Product Development
Design controls are a documented, regulated process covering every phase of the device life cycle. When engineering teams don’t understand these requirements, companies are forced to reverse-engineer design control documentation retroactively — a slower and more expensive process than building it in from the start.
3. Incomplete Technical Documentation and Device Master Files
Complete technical documentation and a device master file are required outputs of the design control process. Gaps here are a direct and preventable cause of submission delays.
4. Inadequate Risk Management Documentation (ISO 14971)
Risk management under ISO 14971 is a critical step for devices of every class. Risk analysis must be considered from the earliest stages of design, not layered on afterward.
5. Insufficient Verification and Validation (V&V) Testing
The scope of verification and validation testing is defined by the device’s risk analysis. All identified V&V studies must be completed, and if results don’t support the device’s performance, a redesign may be required.
6. Missing Usability and Human Factors Engineering Studies
Usability and human factors studies confirm that intended users can handle and operate the device as expected. Skipping these studies is a common and avoidable gap in device submissions.
7. Poor Supplier Qualification and Traceability Systems
Most companies outsource manufacturing of the entire device or its components. Device approval and post-market compliance are only as strong as the qualification and management of suppliers and contract manufacturers.
8. Delayed Implementation of ISO 13485 (or QMSR)
Medical devices must be manufactured under a compliant Quality Management System. This requirement takes effect starting with late-stage device prototypes — before marketing approval — and continues through the entire post-market life cycle.
9. No Clear Regulatory Strategy for FDA, EU MDR, or UKCA
Many companies don’t define their target markets early, so additional countries get added to scope as an afterthought. This is an expensive mistake, since marketing authorization requirements differ by country. Defining target world markets in advance allows a company to leverage shared testing and documentation across regions, saving time and cost.
10. Underestimating the Time, Cost, and Resources Required for Approval
Realistic timelines and budgets depend on clearly defining target markets and their associated regulatory requirements from the start, based on a careful study of applicable regulations, required resources, and timelines.
Frequently Asked Questions
The single biggest reason is treating regulatory compliance as a final step instead of building it into the device design from the concept stage. This mistake compounds into incorrect classification, missing design controls, and incomplete documentation.
In the United States, the FDA classifies devices as Class I, II, or III based on risk. Under the EU Medical Device Regulation (MDR), devices are classified as Class A, B, C, or D. Classification determines the required regulatory pathway and documentation.
Risk management documentation under ISO 14971 should begin at the earliest stages of device design, not after development is complete. Early risk analysis also defines the scope of required verification and validation testing.
.
ISO 13485 or QMSR-compliant Quality Management System requirements take effect starting with late-stage device prototypes, before marketing approval, and continue through the device’s entire post-market life cycle.
Defining target markets such as the U.S. FDA, EU MDR, and UKCA early allows a company to leverage shared testing and documentation across regions. Adding countries as an afterthought is a common and costly mistake because marketing authorization requirements differ by country.
mdi Consultants has provided FDA regulatory consulting to the medical device industry for more than 48 years, helping companies navigate device classification, design controls, risk management, and global regulatory strategy.
About mdi Consultants
mdi Consultants is The Global Regulatory Experts, providing FDA regulatory consulting to the medical device industry for over 48 years. mdi Consultants helps medical device companies address device classification, design controls, risk management, quality systems, and global regulatory strategy across the U.S., EU, and other international markets.
Contact mdi Consultants
If you have questions about your medical device design or FDA/international regulatory compliance, contact mdi Consultants at info@mdiconsultants.com (RE: FDA compliance).
